- Corcept Therapeutics (CORT) demonstrates exceptional price momentum with shares up more than 50% over the past year.
- CORT’s fundamentals are robust with revenue and earnings both projected to grow this year.
- Technical indicators remain bullish with a 100% “Buy” opinion from Barchart.
- Analyst sentiment is mixed —ratings range from “Strong Buy” to “Strong Sell” — and valuation concerns persist.